What Fueled The Previous Growth In The Breast Cancer Liquid Biopsy Market?
The breast cancer liquid biopsy market has seen considerable growth due to a variety of factors.
• Recent years have seen rapid growth in the breast cancer liquid biopsy market. Its size is predicted to expand from $0.78 billion in 2024 to $0.90 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 15.0%.
This previous growth has been driven by developments in next-generation sequencing (ngs), rising occurrences of breast cancer, escalating demand for non-invasive diagnostic processes, growing popularity of personalized medicine, and an uptick in funding for cancer research.
How Does the Forecast Look for the Breast Cancer Liquid Biopsy Market Size?
The breast cancer liquid biopsy market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of the liquid biopsy for breast cancer is projected to undergo quick expansion in the coming years. It is estimated to reach $1.56 billion in 2029, with a compound annual growth rate (CAGR) of 14.7%.
The advancement in technology in liquid biopsy assays, an increase in the early cancer screening using liquid biopsy, the rising need for continuous cancer monitoring, the broadening use in precision oncology, and the growing investment in liquid biopsy R&D, are all factors contributing to this growth during the forecast period. Some key trends for the forecast period are the inclusion of artificial intelligence in liquid biopsy analysis, progress in single-cell sequencing, the creation of multi-omics liquid biopsy platforms, enhancement in the sensitivity and specificity of liquid biopsy, and the usage of digital PCR for ultra-accurate mutation detection.
What Factors Are Driving Growth In The Breast Cancer Liquid Biopsy Market?
The surge in breast cancer incidences is forecasted to stimulate the expansion of the breast cancer liquid biopsy market. Originating in the cells of the breast, particularly in the lobules or ducts, breast cancer is becoming more common due to various reasons such as genetic susceptibility, hormonal imbalances, an aging population, changes in lifestyle, obesity, alcohol intake, sedentary tendencies, radiation exposure, and environmental pollutants. The purpose of a breast cancer liquid biopsy is to trace circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, thereby facilitating real-time disease monitoring. This medical practice is beneficial for evaluating the response to treatment, recognizing resistance to therapy, and pinpointing genetic mutations for tailor-made therapies. For example, the American Cancer Society, a US-based nonprofit organization committed to cancer research, advocacy, education, and patient assistance, predicts that the number of fresh breast cancer cases might reach 319,750 in 2025, an increase from 313,510 cases in 2024. Consequently, the escalating occurrences of breast cancer are fueling the development of the breast cancer liquid biopsy market.
How Are The Segments Defined Within The Global Breast Cancer Liquid Biopsy Market?
The breast cancer liquid biopsy market covered in this report is segmented –
1) By Product: Consumables, Kits
2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers
3) By Application: Early Detection Or Screening, Diagnosis, Other Applications
4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories
Subsegments:
1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits
Pre-Book The Breast Cancer Liquid Biopsy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Breast Cancer Liquid Biopsy Market?
Top companies in the breast cancer liquid biopsy market are strategizing on creating novel products like companion diagnostics. This innovation is aimed at facilitating personalized treatment processes by identifying patients who would gain from specific therapies. Through liquid biopsy technologies, companion diagnostics can discover biomarkers such as genetic variations, circulating tumor DNA (ctDNA), or protein expressions that signal therapy responsiveness. For example, in January 2023, Guardant Health Inc., a biotechnology firm from the US, procured Food and Drug Administration (FDA) authorization for its Guardant360 CDx liquid biopsy test. This became a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a medication for progressive or metastatic breast cancer patients with ESR1 mutations. The FDA's clearance allows oncologists to use the test for extensive genomic profiling, pinpointing patients who could benefit from the precise therapy. This signifies Guardant Health’s inaugural U.S. Food and Drug Administration (FDA) authorization in breast cancer and broadens its influence in precision oncology.
Who Are the Key Players In The Breast Cancer Liquid Biopsy Market?
Major companies operating in the breast cancer liquid biopsy market are:
• Johnson & Johnson Private Limited
• Roche Diagnostics
• Merck KGaA
• Thermo Fisher Scientific
• Siemens Healthineers
• Agilent Technologies Inc.
• Illumina Inc.
• Sysmex Corporation
• Qiagen N.V.
• Myriad Genetics Inc.
• NeoGenomics Laboratories
• Guardant Health Inc.
• Twist Bioscience
• Foundation Medicine Inc.
• Biodesix Inc.
• Menarini Silicon Biosystems
• Datar Cancer Genetics
• Abcam plc
• OncoDNA SA
• Genomic Health Inc.
• RainDance Technologies
• Biocept Inc.
• Fluxion Biosciences Inc.
• Angle plc
What Is The Most Dominant Region In The Breast Cancer Liquid Biopsy Market?
North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
